Home

The laboratory is working on understanding the molecular mechanisms by which acute lymphoblastic leukemia cells survive extensive chemotherapy. We are engaged in several projects using a combination of genetic, bioinformatics and biochemical tools to analyze the functions of specific target proteins and their role in the pathogenesis of acute lymphoblastic leukemia. The goal of our research is to uncover the underlying mechanisms of therapy resistance and to develop less toxic, highly effective molecularly-targeted therapies against acute lymphoblastic leukemia. The lab is mainly focusing on childhood leukemia as this group of patients suffers from long-term side effect of the current therapies.

Read more about us @ Lund University

RECENT PUBLICATIONS:

Shah K, Al-Haidari A, Sun J, Kazi J.U. (2021) T cell receptor (TCR) signaling in health and disease.  Signal Transduct Target Therapy 6(1):412 (PubmedLinkLund UniversityResearchGate).

Rafique R, Islam SMR and Kazi J. U. (2021) Machine learning in the prediction of cancer therapy. Computational and Structural Biotechnology Journal 19:4003-4017 (PubmedLinkLund UniversityResearchGate).

Shah K, Ahmed M and Kazi J. U.  (2021) The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia. npj Precision Oncology 5(1):13 (PubmedLinkLund UniversityResearchGate).

We closely work with:

Rönnstrand Lab